Boron neutron capture therapy for malignant brain tumors.
BNCT
Glioblastoma
Glioma
Meningioma
PET
Review
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
31
05
2020
accepted:
11
07
2020
pubmed:
18
7
2020
medline:
22
6
2021
entrez:
18
7
2020
Statut:
ppublish
Résumé
Boron neutron capture therapy (BNCT) is tumor-selective particle radiation therapy that depends on the nuclear capture and fission reactions. These reactions occur when a non-radioactive boron isotope ( These clinical applications of BNCT have been performed with reactor-based neutron sources over the past decades. We also applied reactor-based BNCT for 58 newly diagnosed glioblastomas and 68 recurrent malignant gliomas including 52 glioblastomas. In this review article, we summarize the clinical results from the literature concerning BNCT for these high-grade gliomas (including our research). We also applied reactor-based BNCT for 46 cases of recurrent and refractory high-grade meningiomas, and some of the results will be presented herein. In Japan, neutron sources have been shifted from reactors to accelerators. Phase 1 and 2 clinical trials have been performed for recurrent malignant gliomas using accelerator-based neutron sources, and now fortunately, a cyclotron-based neutron generator has been approved as a medical device by Japanese regulatory authority, as the world's first accelerator-based BNCT system for medical use. We also discuss the future prospects of accelerator-based BNCT in hospitals as therapy for malignant brain tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Boron neutron capture therapy (BNCT) is tumor-selective particle radiation therapy that depends on the nuclear capture and fission reactions. These reactions occur when a non-radioactive boron isotope (
CLINICAL RESULTS
RESULTS
These clinical applications of BNCT have been performed with reactor-based neutron sources over the past decades. We also applied reactor-based BNCT for 58 newly diagnosed glioblastomas and 68 recurrent malignant gliomas including 52 glioblastomas. In this review article, we summarize the clinical results from the literature concerning BNCT for these high-grade gliomas (including our research). We also applied reactor-based BNCT for 46 cases of recurrent and refractory high-grade meningiomas, and some of the results will be presented herein.
FUTURE PROSPECTS
CONCLUSIONS
In Japan, neutron sources have been shifted from reactors to accelerators. Phase 1 and 2 clinical trials have been performed for recurrent malignant gliomas using accelerator-based neutron sources, and now fortunately, a cyclotron-based neutron generator has been approved as a medical device by Japanese regulatory authority, as the world's first accelerator-based BNCT system for medical use. We also discuss the future prospects of accelerator-based BNCT in hospitals as therapy for malignant brain tumors.
Identifiants
pubmed: 32676954
doi: 10.1007/s11060-020-03586-6
pii: 10.1007/s11060-020-03586-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-11Références
Coderre JA, Morris GM (1999) The radiation biology of boron neutron capture therapy. Radiat Res 151:1–18
doi: 10.2307/3579742
Chadwick J (1932) The existence of a neutron. Proc R Soc Lond 136:692–708
Locher G (1936) Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol 36:1–13
Kruger PG (1940) Some biological effects of nuclear disintegration products on neoplastic tissue. Proc Natl Acad Sci USA 26:181–192. https://doi.org/10.1073/pnas.26.3.181
doi: 10.1073/pnas.26.3.181
pubmed: 16588335
Zahl PA, Cooper FS, Dunning JR (1940) Some in vivo effects of localized nuclear disintegration products on a transplantable mouse sarcoma. Proc Natl Acad Sci USA 26:589–598. https://doi.org/10.1073/pnas.26.10.589
doi: 10.1073/pnas.26.10.589
pubmed: 16577979
Barth RF (2003) A critical assessment of boron neutron capture therapy: an overview. J Neurooncol 62:1–5. https://doi.org/10.1007/BF02699929
doi: 10.1007/BF02699929
pubmed: 12749698
Barth RF, Coderre JA, Vicente MG, Blue TE (2005) Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 11:3987–4002. https://doi.org/10.1158/1078-0432.CCR-05-0035
doi: 10.1158/1078-0432.CCR-05-0035
pubmed: 15930333
Asbury AK, Ojemann RG, Nielsen SL, Sweet WH (1972) Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 31:278–303. https://doi.org/10.1097/00005072-197204000-00005
doi: 10.1097/00005072-197204000-00005
pubmed: 4337274
Farr LE, Sweet WH, Locksley HB, Robertson JS (1954) Neutron capture therapy of gliomas using boron. Trans Am Neurol Assoc 13:110–113
pubmed: 13238328
Goodwin JT, Farr LE, Sweet WH, Robertson JS (1955) Pathological study of eight patients with glioblastoma multiforme treated by neutron-capture therapy using boron 10. Cancer 8:601–615. https://doi.org/10.1002/1097-0142(1955)8:3<601:aid-cncr2820080326>3.0.co;2-r
doi: 10.1002/1097-0142(1955)8:3<601::aid-cncr2820080326>3.0.co;2-r
pubmed: 14379150
Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG (1998) The chemistry of neutron capture therapy. Chem Rev 98:1515–1562. https://doi.org/10.1021/cr941195u
doi: 10.1021/cr941195u
pubmed: 11848941
Ono K, Masunaga SI, Kinashi Y, Takagaki M, Akaboshi M, Kobayashi T, Akuta K (1996) Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy. Int J Radiat Oncol Biol Phys 34:1081–1086. https://doi.org/10.1016/0360-3016(95)02180-9
doi: 10.1016/0360-3016(95)02180-9
pubmed: 8600091
Detta A, Cruickshank GS (2009) L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res 69:2126–2132. https://doi.org/10.1158/0008-5472.CAN-08-2345
doi: 10.1158/0008-5472.CAN-08-2345
pubmed: 19244126
Miyatake S, Kawabata S, Hiramatsu R, Kuroiwa T, Suzuki M, Kondo N, Ono K (2016) Boron neutron capture therapy for malignant brain tumors. Neurol Med Chir (Tokyo) 56:361–371. https://doi.org/10.2176/nmc.ra.2015-0297
doi: 10.2176/nmc.ra.2015-0297
Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T (1998) Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 39:325–333
pubmed: 9476945
Kawabata S, Miyatake S, Kajimoto Y, Kuroda Y, Kuroiwa T, Imahori Y, Kirihata M, Sakurai Y, Kobayashi T, Ono K (2003) The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases. J Neurooncol 65:159–165. https://doi.org/10.1023/b:neon.0000003751.67562.8e
doi: 10.1023/b:neon.0000003751.67562.8e
pubmed: 14686736
Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M, Kuroiwa T, Tsuji M, Imahori Y, Kirihata M, Sakurai Y, Masunaga S, Nagata K, Maruhashi A, Ono K (2005) Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 103:1000–1009. https://doi.org/10.3171/jns.2005.103.6.1000
doi: 10.3171/jns.2005.103.6.1000
pubmed: 16381186
Barth RF, Vicente MG, Harling OK, Kiger WS 3rd, Riley KJ, Binns PJ, Wagner FM, Suzuki M, Aihara T, Kato I, Kawabata S (2012) Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 7:146. https://doi.org/10.1186/1748-717X-7-146
doi: 10.1186/1748-717X-7-146
pubmed: 22929110
pmcid: 3583064
Suzuki M (2020) Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era. Int J Clin Oncol 25:43–50. https://doi.org/10.1007/s10147-019-01480-4
doi: 10.1007/s10147-019-01480-4
pubmed: 31168726
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
doi: 10.1056/NEJMoa043330
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345
doi: 10.1056/NEJMoa1308345
pubmed: 24552318
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573
doi: 10.1056/NEJMoa1308573
pubmed: 24552317
pmcid: 4201043
Kawabata S, Miyatake S, Hiramatsu R, Hirota Y, Miyata S, Takekita Y, Kuroiwa T, Kirihata M, Sakurai Y, Maruhashi A, Ono K (2011) Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme—study design and current status report. Appl Radiat Isot 69:1796–1799. https://doi.org/10.1016/j.apradiso.2011.03.014
doi: 10.1016/j.apradiso.2011.03.014
pubmed: 21459588
Kawabata S, Miyatake S, Kuroiwa T, Yokoyama K, Doi A, Iida K, Miyata S, Nonoguchi N, Michiue H, Takahashi M, Inomata T, Imahori Y, Kirihata M, Sakurai Y, Maruhashi A, Kumada H, Ono K (2009) Boron neutron capture therapy for newly diagnosed glioblastoma (Tokyo). J Radiat Res 50:51–60. https://doi.org/10.1269/jrr.08043
doi: 10.1269/jrr.08043
pubmed: 18957828
Carson KA, Grossman SA, Fisher JD, Shaw EG (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25:2601–2606. https://doi.org/10.1200/JCO.2006.08.1661
doi: 10.1200/JCO.2006.08.1661
pubmed: 17577040
pmcid: 4118746
Miyatake S, Kawabata S, Nonoguchi N, Yokoyama K, Kuroiwa T, Matsui H, Ono K (2009) Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol 11:430–436. https://doi.org/10.1215/15228517-2008-107
doi: 10.1215/15228517-2008-107
pubmed: 19289492
pmcid: 2743223
Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y, Kumada H, Suzuki M, Maruhashi A, Kirihata M, Ono K (2009) Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol 91:199–206. https://doi.org/10.1007/s11060-008-9699-x
doi: 10.1007/s11060-008-9699-x
pubmed: 18813875
Furuse M, Kawabata S, Kuroiwa T, Miyatake S (2011) Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 102:471–475. https://doi.org/10.1007/s11060-010-0333-3
doi: 10.1007/s11060-010-0333-3
pubmed: 20694573
Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487–1495. https://doi.org/10.1016/j.ijrobp.2009.12.061
doi: 10.1016/j.ijrobp.2009.12.061
pubmed: 20399573
pmcid: 2908725
Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, Miwa K, Iuchi T, Tsuboi K, Houkin K, Terasaka S, Tabei Y, Nakamura H, Nagane M, Sugiyama K, Terasaki M, Abe T, Narita Y, Saito N, Mukasa A, Ogasawara K, Beppu T, Kumabe T, Nariai T, Tsuyuguchi N, Nakatani E, Kurisu S, Nakagawa Y, Miyatake S (2016) A prospective multicenter single-arm clinical trial of bevacizumab for patients with surgically untreatable symptomatic brain radiation necrosis. Neurooncol Pract 3:272–280. https://doi.org/10.1093/nop/npv064
doi: 10.1093/nop/npv064
pubmed: 27833757
pmcid: 5099992
Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, Ono K (2013) Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases. Neuro Oncol 15:650–655. https://doi.org/10.1093/neuonc/not020
doi: 10.1093/neuonc/not020
pubmed: 23460324
pmcid: 3661101
Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M (2014) Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases. Radiat Oncol 9:6. https://doi.org/10.1186/1748-717X-9-6
doi: 10.1186/1748-717X-9-6
pubmed: 24387301
pmcid: 3923505
Shiba H, Takeuchi K, Hiramatsu R, Furuse M, Nonoguchi N, Kawabata S, Kuroiwa T, Kondo N, Sakurai Y, Suzuki M, Ono K, Oue S, Ishikawa E, Michiue H, Miyatake SI (2018) Boron neutron capture therapy combined with early successive bevacizumab treatments for recurrent malignant gliomas—a pilot study. Neurol Med Chir (Tokyo) 58:487–494. https://doi.org/10.2176/nmc.oa.2018-0111
doi: 10.2176/nmc.oa.2018-0111
Jaaskelainen J, Haltia M, Servo A (1986) Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25:233–242. https://doi.org/10.1016/0090-3019(86)90233-8
doi: 10.1016/0090-3019(86)90233-8
pubmed: 3945904
Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A (2015) Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 17:116–121. https://doi.org/10.1093/neuonc/nou148
doi: 10.1093/neuonc/nou148
pubmed: 25100872
Chamberlain MC (2012) The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma. Curr Opin Oncol 24:666–671. https://doi.org/10.1097/CCO.0b013e328356364d
doi: 10.1097/CCO.0b013e328356364d
pubmed: 22759739
Kawabata S, Hiramatsu R, Kuroiwa T, Ono K, Miyatake SI (2013) Boron neutron capture therapy for recurrent high-grade meningiomas. J Neurosurg 119:837–844. https://doi.org/10.3171/2013.5.JNS122204
doi: 10.3171/2013.5.JNS122204
pubmed: 23808536
Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K (2007) Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery 61:82–90. https://doi.org/10.1227/01.neu.0000279727.90650.24 (discussion 90–81)
doi: 10.1227/01.neu.0000279727.90650.24
pubmed: 17621022
Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A, Kuroiwa T, Asada M, Tanabe H, Ono K (2006) Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg 105:898–903. https://doi.org/10.3171/jns.2006.105.6.898
doi: 10.3171/jns.2006.105.6.898
pubmed: 17405262
Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, Ono K, Harada T (2006) First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck 28:850–855. https://doi.org/10.1002/hed.20418
doi: 10.1002/hed.20418
pubmed: 16721735
Kankaanranta L, Saarilahti K, Makitie A, Valimaki P, Tenhunen M, Joensuu H (2011) Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement. Radiother Oncol 99:98–99. https://doi.org/10.1016/j.radonc.2011.02.008
doi: 10.1016/j.radonc.2011.02.008
pubmed: 21397966
Kankaanranta L, Seppala T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Valimaki P, Makitie A, Seppanen M, Minn H, Revitzer H, Kouri M, Kotiluoto P, Seren T, Auterinen I, Savolainen S, Joensuu H (2012) Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys 82:e67–e75. https://doi.org/10.1016/j.ijrobp.2010.09.057
doi: 10.1016/j.ijrobp.2010.09.057
pubmed: 21300462
Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M, Yura Y (2004) Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 61:1069–1073. https://doi.org/10.1016/j.apradiso.2004.05.059
doi: 10.1016/j.apradiso.2004.05.059
pubmed: 15308194
Koivunoro H, Kankaanranta L, Seppala T, Haapaniemi A, Makitie A, Joensuu H (2019) Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: an analysis of dose response and survival. Radiother Oncol 137:153–158. https://doi.org/10.1016/j.radonc.2019.04.033
doi: 10.1016/j.radonc.2019.04.033
pubmed: 31108276
Wang LW, Wang SJ, Chu PY, Ho CY, Jiang SH, Liu YW, Liu YH, Liu HM, Peir JJ, Chou FI, Yen SH, Lee YL, Chang CW, Liu CS, Chen YW, Ono K (2011) BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor. Appl Radiat Isot 69:1803–1806. https://doi.org/10.1016/j.apradiso.2011.03.008
doi: 10.1016/j.apradiso.2011.03.008
pubmed: 21478023
International Atomic Energy Agency (IAEA) (2001) IAEA-TECDOC-1223. Current status of neutron capture therapy. ISSN: 1011-4289. https://www-pub.iaea.org/MTCD/publications/PDF/te_1223_prn.pdf . Accessed 19 May 2020
Forton E, Stichelbaut F, Cambriani A, Kleeven W, Ahlback J, Jongen Y (2009) Overview of the IBA accelerator-based BNCT system. Appl Radiat Isot 67:S262–S265. https://doi.org/10.1016/j.apradiso.2009.03.099
doi: 10.1016/j.apradiso.2009.03.099
pubmed: 19376728
Kumada H, Matsumura A, Sakurai H, Sakae T, Yoshioka M, Kobayashi H, Matsumoto H, Kiyanagi Y, Shibata T, Nakashima H (2014) Project for the development of the linac based NCT facility in University of Tsukuba. Appl Radiat Isot 88:211–215. https://doi.org/10.1016/j.apradiso.2014.02.018
doi: 10.1016/j.apradiso.2014.02.018
pubmed: 24637084
Tanaka H, Sakurai Y, Suzuki M, Masunaga S, Kinashi Y, Kashino G, Liu Y, Mitsumoto T, Yajima S, Tsutsui H, Maruhashi A, Ono K (2009) Characteristics comparison between a cyclotron-based neutron source and KUR-HWNIF for boron neutron capture therapy. Nucl Instrum Methods Phys Res B 267:1970–1977. https://doi.org/10.1016/j.nimb.2009.03.095
doi: 10.1016/j.nimb.2009.03.095
Sumitomo Heavy Industries, Ltd. obtains medical device approval for manufacturing and sales of accelerator based BNCT system and the dose calculation program in Japan. World’s first BNCT system as medical device. https://www.shi.co.jp/english/info/2019/6kgpsq0000002ji0.html . Accessed 19 May 2020
Stella Pharma Receives Marketing and Manufacturing Approval in Japan for Steboronine
Altieri S, Balzi M, Bortolussi S, Bruschi P, Ciani L, Clerici AM, Faraoni P, Ferrari C, Gadan MA, Panza L, Pietrangeli D, Ricciardi G, Ristori S (2009) Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. J Med Chem 52:7829–7835. https://doi.org/10.1021/jm900763b
doi: 10.1021/jm900763b
pubmed: 19954249
Li T, Hamdi J, Hawthorne MF (2006) Unilamellar liposomes with enhanced boron content. Bioconjug Chem 17:15–20. https://doi.org/10.1021/bc0501350
doi: 10.1021/bc0501350
pubmed: 16417247
Crossley EL, Ziolkowski EJ, Coderre JA, Rendina LM (2007) Boronated DNA-binding compounds as potential agents for boron neutron capture therapy. Mini Rev Med Chem 7:303–313. https://doi.org/10.2174/138955707780059808
doi: 10.2174/138955707780059808
pubmed: 17346220
Hiramatsu R, Kawabata S, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake S, Kuroiwa T, Hao E, Vicente MG (2015) Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): application for photodynamic therapy and boron neutron capture therapy. J Pharm Sci 104:962–970. https://doi.org/10.1002/jps.24317
doi: 10.1002/jps.24317
pubmed: 28756849
Renner MW, Miura M, Easson MW, Vicente MG (2006) Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy. Anticancer Agents Med Chem 6:145–157. https://doi.org/10.2174/187152006776119135
doi: 10.2174/187152006776119135
pubmed: 16529537
Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W, Barth RF, Claffey K, Backer JM (2005) Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 4:1423–1429. https://doi.org/10.1158/1535-7163.MCT-05-0161
doi: 10.1158/1535-7163.MCT-05-0161
pubmed: 16170035
Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ (2006) Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 12:3792–3802. https://doi.org/10.1158/1078-0432.CCR-06-0141
doi: 10.1158/1078-0432.CCR-06-0141
pubmed: 16778107
Yang W, Barth RF, Wu G, Tjarks W, Binns P, Riley K (2009) Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot 67:S328–S331. https://doi.org/10.1016/j.apradiso.2009.03.030
doi: 10.1016/j.apradiso.2009.03.030
pubmed: 19467880
Michiue H, Sakurai Y, Kondo N, Kitamatsu M, Bin F, Nakajima K, Hirota Y, Kawabata S, Nishiki T, Ohmori I, Tomizawa K, Miyatake S, Ono K, Matsui H (2014) The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials 35:3396–3405. https://doi.org/10.1016/j.biomaterials.2013.12.055
doi: 10.1016/j.biomaterials.2013.12.055
pubmed: 24452095
Nomoto T, Inoue Y, Yao Y, Suzuki M, Kanamori K, Takemoto H, Matsui M, Tomoda K, Nishiyama N (2020) Poly(vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism. Sci Adv 6:eaaz1722. https://doi.org/10.1126/sciadv.aaz1722
doi: 10.1126/sciadv.aaz1722
pubmed: 32010792
pmcid: 6976296
Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, Liu HB, Wielopolski L, Chanana AD (1998) Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys 40:829–834. https://doi.org/10.1016/s0360-3016(97)00891-2
doi: 10.1016/s0360-3016(97)00891-2
pubmed: 9531367
Chanana AD, Capala J, Chadha M, Coderre JA, Diaz AZ, Elowitz EH, Iwai J, Joel DD, Liu HB, Ma R, Pendzick N, Peress NS, Shady MS, Slatkin DN, Tyson GW, Wielopolski L (1999) Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery 44:1182–1192. https://doi.org/10.1097/00006123-199906000-00013 (discussion 1192–1183)
doi: 10.1097/00006123-199906000-00013
pubmed: 10371617
Coderre JA, Turcotte JC, Riley KJ, Binns PJ, Harling OK, Kiger WS 3rd (2003) Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation. Technol Cancer Res Treat 2:355–375. https://doi.org/10.1177/153303460300200502
doi: 10.1177/153303460300200502
pubmed: 14529302
Diaz AZ (2003) Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view. J Neurooncol 62:101–109. https://doi.org/10.1007/BF02699937
doi: 10.1007/BF02699937
pubmed: 12749706
Busse PM, Harling OK, Palmer MR, Kiger WS 3rd, Kaplan J, Kaplan I, Chuang CF, Goorley JT, Riley KJ, Newton TH, Santa Cruz GA, Lu XQ, Zamenhof RG (2003) A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neurooncol 62:111–121. https://doi.org/10.1007/BF02699938
doi: 10.1007/BF02699938
pubmed: 12749707
Palmer MR, Goorley JT, Kiger WS, Busse PM, Riley KJ, Harling OK, Zamenhof RG (2002) Treatment planning and dosimetry for the Harvard-MIT phase I clinical trial of cranial neutron capture therapy. Int J Radiat Oncol Biol Phys 53:1361–1379. https://doi.org/10.1016/s0360-3016(02)02862-6
doi: 10.1016/s0360-3016(02)02862-6
pubmed: 12128139
Kiger WS 3rd, Lu XQ, Harling OK, Riley KJ, Binns PJ, Kaplan J, Patel H, Zamenhof RG, Shibata Y, Kaplan ID, Busse PM, Palmer MR (2004) Preliminary treatment planning and dosimetry for a clinical trial of neutron capture therapy using a fission converter epithermal neutron beam. Appl Radiat Isot 61:1075–1081. https://doi.org/10.1016/j.apradiso.2004.05.008
doi: 10.1016/j.apradiso.2004.05.008
pubmed: 15308195
Vos MJ, Turowski B, Zanella FE, Paquis P, Siefert A, Hideghety K, Haselsberger K, Grochulla F, Postma TJ, Wittig A, Heimans JJ, Slotman BJ, Vandertop WP, Sauerwein W (2005) Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. Int J Radiat Oncol Biol Phys 61:392–399. https://doi.org/10.1016/j.ijrobp.2004.06.008
doi: 10.1016/j.ijrobp.2004.06.008
pubmed: 15667958
Joensuu H, Kankaanranta L, Seppala T, Auterinen I, Kallio M, Kulvik M, Laakso J, Vahatalo J, Kortesniemi M, Kotiluoto P, Seren T, Karila J, Brander A, Jarviluoma E, Ryynanen P, Paetau A, Ruokonen I, Minn H, Tenhunen M, Jaaskelainen J, Farkkila M, Savolainen S (2003) Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neurooncol 62:123–134. https://doi.org/10.1007/BF02699939
doi: 10.1007/BF02699939
pubmed: 12749708
Kankaanranta L, Seppala T, Koivunoro H, Valimaki P, Beule A, Collan J, Kortesniemi M, Uusi-Simola J, Kotiluoto P, Auterinen I, Seren T, Paetau A, Saarilahti K, Savolainen S, Joensuu H (2011) L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a phase I study. Int J Radiat Oncol Biol Phys 80:369–376. https://doi.org/10.1016/j.ijrobp.2010.02.031
doi: 10.1016/j.ijrobp.2010.02.031
pubmed: 21236605
Capala J, Barth RF, Bendayan M, Lauzon M, Adams DM, Soloway AH, Fenstermaker RA, Carlsson J (1996) Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug Chem 7:7–15. https://doi.org/10.1021/bc950077q
doi: 10.1021/bc950077q
pubmed: 8741985
Henriksson R, Capala J, Michanek A, Lindahl SK, Salford LG, Franzen L, Blomquist E, Westlin JE, Bergenheim AT (2008) Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 88:183–191. https://doi.org/10.1016/j.radonc.2006.04.015
doi: 10.1016/j.radonc.2006.04.015
pubmed: 18336940
Skold K, Stenstam BH, Diaz AZ, Giusti V, Pellettieri L, Hopewell JW (2010) Boron neutron capture therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. Acta Neurol Scand 122:58–62. https://doi.org/10.1111/j.1600-0404.2009.01267.x
doi: 10.1111/j.1600-0404.2009.01267.x
pubmed: 19951268
Skold K, Gorlia T, Pellettieri L, Giusti V, Stenstam BH, Hopewell JW (2010) Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br J Radiol 83:596–603. https://doi.org/10.1259/bjr/56953620
doi: 10.1259/bjr/56953620
pubmed: 20603410
pmcid: 3473677
Pellettieri L, Stenstam BH, Rezaei A, Giusti V, Skold K (2008) An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand 117:191–197. https://doi.org/10.1111/j.1600-0404.2007.00924.x
doi: 10.1111/j.1600-0404.2007.00924.x
pubmed: 18297764
Yamamoto T, Matsumura A, Nakai K, Shibata Y, Endo K, Sakurai F, Kishi T, Kumada H, Yamamoto K, Torii Y (2004) Current clinical results of the Tsukuba BNCT trial. Appl Radiat Isot 61:1089–1093. https://doi.org/10.1016/j.apradiso.2004.05.010
doi: 10.1016/j.apradiso.2004.05.010
pubmed: 15308197
Yamamoto T, Nakai K, Kageji T, Kumada H, Endo K, Matsuda M, Shibata Y, Matsumura A (2009) Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol 91:80–84. https://doi.org/10.1016/j.radonc.2009.02.009
doi: 10.1016/j.radonc.2009.02.009
pubmed: 19285355
Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H (2011) Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT). Appl Radiat Isot 69:1800–1802. https://doi.org/10.1016/j.apradiso.2011.03.021
doi: 10.1016/j.apradiso.2011.03.021
pubmed: 21463946
Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H (2011) Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. Appl Radiat Isot 69:1823–1825. https://doi.org/10.1016/j.apradiso.2011.05.029
doi: 10.1016/j.apradiso.2011.05.029
pubmed: 21684170
Kageji T, Nagahiro S, Matsuzaki K, Mizobuchi Y, Toi H, Nakagawa Y, Kumada H (2006) Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma—correlation between radiation dose and radiation injury and clinical outcome. Int J Radiat Oncol Biol Phys 65:1446–1455. https://doi.org/10.1016/j.ijrobp.2006.03.016
doi: 10.1016/j.ijrobp.2006.03.016
pubmed: 16750328